The Principles of Engineering Immune Cells to Treat Cancer

Cell

Volumn 168, Issue 4, 2017, Pages 724-740

  Lim, Wendell A ^a   June, Carl H ^b  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CELL ANTIGEN; CHECKPOINT KINASE INHIBITOR; CHIMERIC ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL ENGINEERING; CROSS REACTION; FEEDBACK SYSTEM; HUMAN; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SYNTHETIC BIOLOGY; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; CYTOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASMS; PERSONALIZED MEDICINE; PROCEDURES;

ANIMALS; ANTIGENS, CD19; CELL ENGINEERING; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; PRECISION MEDICINE; RECEPTORS, ANTIGEN, T-CELL; SYNTHETIC BIOLOGY; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 85012023606     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.01.016     Document Type: Review

References (149)

1. Ahmed, N., Brawley, V.S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J. Clin. Oncol. 33 (2015), 1688–1696.
2. Akbar, A.N., Henson, S.M., Are senescence and exhaustion intertwined or unrelated processes that compromise immunity?. Nat. Rev. Immunol. 11 (2011), 289–295.
3. Aleksic, M., Liddy, N., Molloy, P.E., Pumphrey, N., Vuidepot, A., Chang, K.M., Jakobsen, B.K., Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur. J. Immunol. 42 (2012), 3174–3179.
4. Ali, S.A., Shi, V., Maric, I., Wang, M., Stroncek, D.F., Rose, J.J., Brudno, J.N., Stetler-Stevenson, M., Feldman, S.A., Hansen, B.G., et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128 (2016), 1688–1700.
5. Barrett, D.M., Singh, N., Liu, X., Jiang, S., June, C.H., Grupp, S.A., Zhao, Y., Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. Cytotherapy 16 (2014), 619–630.
6. Bashor, C.J., Helman, N.C., Yan, S., Lim, W.A., Using engineered scaffold interactions to reshape MAP kinase pathway signaling dynamics. Science 319 (2008), 1539–1543.
7. Bendle, G.M., Linnemann, C., Hooijkaas, A.I., Bies, L., de Witte, M.A., Jorritsma, A., Kaiser, A.D.M., Pouw, N., Debets, R., Kieback, E., et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16 (2010), 565–570 1p, 570.
8. Boice, M., Salloum, D., Mourcin, F., Sanghvi, V., Amin, R., Oricchio, E., Jiang, M., Mottok, A., Denis-Lagache, N., Ciriello, G., Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell 167 (2016), 405–418.
9. Bregni, M., Ueno, N.T., Childs, R., The second international meeting on allogeneic transplantation in solid tumors. Bone Marrow Transplant. 38 (2006), 527–537.
10. Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med., 5, 2013, 177ra38.
11. Brudno, J.N., Somerville, R.P., Shi, V., Rose, J.J., Halverson, D.C., Fowler, D.H., Gea-Banacloche, J.C., Pavletic, S.Z., Hickstein, D.D., Lu, T.L., et al. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. J. Clin. Oncol. 34 (2016), 1112–1121.
12. Buck, M.D., O'Sullivan, D., Klein Geltink, R.I., Curtis, J.D., Chang, C.H., Sanin, D.E., Qiu, J., Kretz, O., Braas, D., van der Windt, G.J., et al. Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming. Cell 166 (2016), 63–76.
13. Cameron, B.J., Gerry, A.B., Dukes, J., Harper, J.V., Kannan, V., Bianchi, F.C., Grand, F., Brewer, J.E., Gupta, M., Plesa, G., et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med., 5, 2013, 197ra103.
14. Carr, E.L., Kelman, A., Wu, G.S., Gopaul, R., Senkevitch, E., Aghvanyan, A., Turay, A.M., Frauwirth, K.A., Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J. Immunol. 185 (2010), 1037–1044.
15. Caruso, H.G., Hurton, L.V., Najjar, A., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K., Singh, H., Huls, H., et al. Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res. 75 (2015), 3505–3518.
16. Cekic, C., Sag, D., Day, Y.-J., Linden, J., Extracellular adenosine regulates naive T cell development and peripheral maintenance. J. Exp. Med. 210 (2013), 2693–2706.
17. Chang, C.H., Qiu, J., O'Sullivan, D., Buck, M.D., Noguchi, T., Curtis, J.D., Chen, Q., Gindin, M., Gubin, M.M., van der Windt, G.J., et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell 162 (2015), 1229–1241.
18. ∗0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J. Immunol. 186 (2011), 685–696.
19. Chong, E.A., Melenhorst, J.J., Lacey, S.F., Ambrose, D.E., Gonzalez, V., Levine, B., June, C.H., Schuster, S.J., PD-1 Blockade Modulates Chimeric Antigen Receptor (CAR) Modified T Cells and Induces Tumor Regression: Refueling the CAR. Blood, 2016 blood-2016-09-738245, http://dx.doi.org/10.1182/blood-2016-09-738245.
20. Collins, R.H. Jr., Shpilberg, O., Drobyski, W.R., Porter, D.L., Giralt, S., Champlin, R., Goodman, S.A., Wolff, S.N., Hu, W., Verfaillie, C., et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15 (1997), 433–444.
21. Coulie, P.G., Van den Eynde, B.J., van der Bruggen, P., Boon, T., Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14 (2014), 135–146.
22. Crespo, J., Sun, H., Welling, T.H., Tian, Z., Zou, W., T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 25 (2013), 214–221.
23. Di Stasi, A., De Angelis, B., Rooney, C.M., Zhang, L., Mahendravada, A., Foster, A.E., Heslop, H.E., Brenner, M.K., Dotti, G., Savoldo, B., T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113 (2009), 6392–6402.
24. Di Stasi, A., Tey, S.K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A.G., Grilley, B., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365 (2011), 1673–1683.
25. Eil, R., Vodnala, S.K., Clever, D., Klebanoff, C.A., Sukumar, M., Pan, J.H., Palmer, D.C., Gros, A., Yamamoto, T.N., Patel, S.J., et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537 (2016), 539–543.
26. Engel, P., Zhou, L.J., Ord, D.C., Sato, S., Koller, B., Tedder, T.F., Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3 (1995), 39–50.
27. Fedorov, V.D., Themeli, M., Sadelain, M., PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med., 5, 2013, 215ra172.
28. Ferrara, J.L., Levine, J.E., Reddy, P., Holler, E., Graft-versus-host disease. Lancet 373 (2009), 1550–1561.
29. Fischbach, M.A., Bluestone, J.A., Lim, W.A., Cell-based therapeutics: the next pillar of medicine. Sci. Transl. Med., 5, 2013, 179ps7.
30. Fitzgerald, J.C., Weiss, S.L., Maude, S.L., Barrett, D.M., Lacey, S.F., Melenhorst, J.J., Shaw, P., Berg, R.A., June, C.H., Porter, D.L., et al. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit. Care Med. 45 (2016), e124–e131.
31. Foster, A.E., Dotti, G., Lu, A., Khalil, M., Brenner, M.K., Heslop, H.E., Rooney, C.M., Bollard, C.M., Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J. Immunother. 31 (2008), 500–505.
32. Fox, C.J., Hammerman, P.S., Thompson, C.B., Fuel feeds function: energy metabolism and the T-cell response. Nat. Rev. Immunol. 5 (2005), 844–852.
33. Frauwirth, K.A., Riley, J.L., Harris, M.H., Parry, R.V., Rathmell, J.C., Plas, D.R., Elstrom, R.L., June, C.H., Thompson, C.B., The CD28 signaling pathway regulates glucose metabolism. Immunity 16 (2002), 769–777.
34. Fritsch, R.D., Shen, X., Sims, G.P., Hathcock, K.S., Hodes, R.J., Lipsky, P.E., Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J. Immunol. 175 (2005), 6489–6497.
35. Geiger, R., Rieckmann, J.C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., et al. L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. Cell 167 (2016), 829–842.
36. Gianni, L., Herman, E.H., Lipshultz, S.E., Minotti, G., Sarvazyan, N., Sawyer, D.B., Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol. 26 (2008), 3777–3784.
37. Grada, Z., Hegde, M., Byrd, T., Shaffer, D.R., Ghazi, A., Brawley, V.S., Corder, A., Schönfeld, K., Koch, J., Dotti, G., et al. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol. Ther. Nucleic Acids, 2, 2013, e105.
38. Gross, G., Waks, T., Eshhar, Z., Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl. Acad. Sci. USA 86 (1989), 10024–10028.
39. Guedan, S., Chen, X., Madar, A., Carpenito, C., McGettigan, S.E., Frigault, M.J., Lee, J., Posey, A.D. Jr., Scholler, J., Scholler, N., et al. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. Blood 124 (2014), 1070–1080.
40. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
41. Hickman, E.S., Lomax, M.E., Jakobsen, B.K., Antigen Selection for Enhanced Affinity T-Cell Receptor-Based Cancer Therapies. J. Biomol. Screen. 21 (2016), 769–785.
42. Ho, P.C., Bihuniak, J.D., Macintyre, A.N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.C., Cui, G., Micevic, G., Perales, J.C., et al. Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell 162 (2015), 1217–1228.
43. Hombach, A.A., Rappl, G., Abken, H., Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 “super-stimulation”. Mol. Ther. 21 (2013), 2268–2277.
44. Hurton, L.V., Singh, H., Najjar, A.M., Switzer, K.C., Mi, T., Maiti, S., Olivares, S., Rabinovich, B., Huls, H., Forget, M.A., et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc. Natl. Acad. Sci. USA 113 (2016), E7788–E7797.
45. Im, S.J., Hashimoto, M., Gerner, M.Y., Lee, J., Kissick, H.T., Burger, M.C., Shan, Q., Hale, J.S., Lee, J., Nasti, T.H., et al. Defining CD8(+) T cells that provide the proliferative burst after PD-1 therapy. Nature 537 (2016), 417–421.
46. Jacoby, E., Nguyen, S.M., Fountaine, T.J., Welp, K., Gryder, B., Qin, H., Yang, Y., Chien, C.D., Seif, A.E., Lei, H., et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat. Commun., 7, 2016, 12320.
47. John, L.B., Devaud, C., Duong, C.P., Yong, C.S., Beavis, P.A., Haynes, N.M., Chow, M.T., Smyth, M.J., Kershaw, M.H., Darcy, P.K., Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19 (2013), 5636–5646.
48. Johnson, L.A., Morgan, R.A., Dudley, M.E., Cassard, L., Yang, J.C., Hughes, M.S., Kammula, U.S., Royal, R.E., Sherry, R.M., Wunderlich, J.R., et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114 (2009), 535–546.
49. Joyce, J.A., Fearon, D.T., T cell exclusion, immune privilege, and the tumor microenvironment. Science 348 (2015), 74–80.
50. June, C.H., Principles of adoptive T cell cancer therapy. J. Clin. Invest. 117 (2007), 1204–1212.
51. Kageyama, S., Ikeda, H., Miyahara, Y., Imai, N., Ishihara, M., Saito, K., Sugino, S., Ueda, S., Ishikawa, T., Kokura, S., et al. Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin. Cancer Res. 21 (2015), 2268–2277.
52. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., June, C.H., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med., 3, 2011, 95ra73.
53. Kawalekar, O.U., O'Connor, R.S., Fraietta, J.A., Guo, L., McGettigan, S.E., Posey, A.D. Jr., Patel, P.R., Guedan, S., Scholler, J., Keith, B., et al. Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. Immunity 44 (2016), 380–390.
54. Kerkar, S.P., Muranski, P., Kaiser, A., Boni, A., Sanchez-Perez, L., Yu, Z., Palmer, D.C., Reger, R.N., Borman, Z.A., Zhang, L., et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70 (2010), 6725–6734.
55. Kershaw, M.H., Westwood, J.A., Parker, L.L., Wang, G., Eshhar, Z., Mavroukakis, S.A., White, D.E., Wunderlich, J.R., Canevari, S., Rogers-Freezer, L., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12 (2006), 6106–6115.
56. Klebanoff, C.A., Rosenberg, S.A., Restifo, N.P., Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat. Med. 22 (2016), 26–36.
57. Kloss, C.C., Condomines, M., Cartellieri, M., Bachmann, M., Sadelain, M., Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31 (2013), 71–75.
58. Kochenderfer, J.N., Wilson, W.H., Janik, J.E., Dudley, M.E., Stetler-Stevenson, M., Feldman, S.A., Maric, I., Raffeld, M., Nathan, D.A., Lanier, B.J., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116 (2010), 4099–4102.
59. Kudo, K., Imai, C., Lorenzini, P., Kamiya, T., Kono, K., Davidoff, A.M., Chng, W.J., Campana, D., T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res. 74 (2014), 93–103.
60. Kuwana, Y., Asakura, Y., Utsunomiya, N., Nakanishi, M., Arata, Y., Itoh, S., Nagase, F., Kurosawa, Y., Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem. Biophys. Res. Commun. 149 (1987), 960–968.
61. Lamers, C.H., Sleijfer, S., Vulto, A.G., Kruit, W.H., Kliffen, M., Debets, R., Gratama, J.W., Stoter, G., Oosterwijk, E., Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24 (2006), e20–e22.
62. Lamers, C.H., Willemsen, R., van Elzakker, P., van Steenbergen-Langeveld, S., Broertjes, M., Oosterwijk-Wakka, J., Oosterwijk, E., Sleijfer, S., Debets, R., Gratama, J.W., Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117 (2011), 72–82.
63. Lamers, C.H., Sleijfer, S., van Steenbergen, S., van Elzakker, P., van Krimpen, B., Groot, C., Vulto, A., den Bakker, M., Oosterwijk, E., Debets, R., Gratama, J.W., Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 21 (2013), 904–912.
64. Lanitis, E., Poussin, M., Klattenhoff, A.W., Song, D., Sandaltzopoulos, R., June, C.H., Powell, D.J. Jr., Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol. Res. 1 (2013), 43–53.
65. Lee, P.P., Yee, C., Savage, P.A., Fong, L., Brockstedt, D., Weber, J.S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P.D., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5 (1999), 677–685.
66. Lee, D.W., Gardner, R., Porter, D.L., Louis, C.U., Ahmed, N., Jensen, M., Grupp, S.A., Mackall, C.L., Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124 (2014), 188–195.
67. Levine, B.L., Bernstein, W.B., Aronson, N.E., Schlienger, K., Cotte, J., Perfetto, S., Humphries, M.J., Ratto-Kim, S., Birx, D.L., Steffans, C., et al. Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat. Med. 8 (2002), 47–53.
68. Li, Y., Zhi, W., Wareski, P., Weng, N.P., IL-15 activates telomerase and minimizes telomere loss and may preserve the replicative life span of memory CD8+ T cells in vitro. J. Immunol. 174 (2005), 4019–4024.
69. Linette, G.P., Stadtmauer, E.A., Maus, M.V., Rapoport, A.P., Levine, B.L., Emery, L., Litzky, L., Bagg, A., Carreno, B.M., Cimino, P.J., et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122 (2013), 863–871.
70. Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E.C., Cogdill, A.P., Li, N., Ramones, M., Granda, B., et al. Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. Cancer Res. 75 (2015), 3596–3607.
71. Ma, J.S., Kim, J.Y., Kazane, S.A., Choi, S.H., Yun, H.Y., Kim, M.S., Rodgers, D.T., Pugh, H.M., Singer, O., Sun, S.B., et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc. Natl. Acad. Sci. USA 113 (2016), E450–E458.
72. Mahoney, K.M., Rennert, P.D., Freeman, G.J., Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14 (2015), 561–584.
73. Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 (2014), 1507–1517.
74. Mitsuyasu, R.T., Anton, P.A., Deeks, S.G., Scadden, D.T., Connick, E., Downs, M.T., Bakker, A., Roberts, M.R., June, C.H., Jalali, S., et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 96 (2000), 785–793.
75. Mondal, A.M., Horikawa, I., Pine, S.R., Fujita, K., Morgan, K.M., Vera, E., Mazur, S.J., Appella, E., Vojtesek, B., Blasco, M.A., et al. p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J. Clin. Invest. 123 (2013), 5247–5257.
76. Moon, E., Carpenito, C., Sun, J., Wang, L., Kapoor, V., Predina, J., Powell, D. Jr., Riley, J., June, C.H., Albelda, S.M., Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17 (2011), 4719–4730.
77. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006), 126–129.
78. Morgan, R.A., Yang, J.C., Kitano, M., Dudley, M.E., Laurencot, C.M., Rosenberg, S.A., Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18 (2010), 843–851.
79. Morgan, R.A., Chinnasamy, N., Abate-Daga, D., Gros, A., Robbins, P.F., Zheng, Z., Dudley, M.E., Feldman, S.A., Yang, J.C., Sherry, R.M., et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36 (2013), 133–151.
80. Morsut, L., Roybal, K.T., Xiong, X., Gordley, R.M., Coyle, S.M., Thomson, M., Lim, W.A., Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors. Cell 164 (2016), 780–791.
81. Muranski, P., Boni, A., Antony, P.A., Cassard, L., Irvine, K.R., Kaiser, A., Paulos, C.M., Palmer, D.C., Touloukian, C.E., Ptak, K., et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112 (2008), 362–373.
82. Narayanan, P., Lapteva, N., Seethammagari, M., Levitt, J.M., Slawin, K.M., Spencer, D.M., A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J. Clin. Invest. 121 (2011), 1524–1534.
83. Odorizzi, P.M., Pauken, K.E., Paley, M.A., Sharpe, A., Wherry, E.J., Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J. Exp. Med. 212 (2015), 1125–1137.
84. Omazic, B., Remberger, M., Barkholt, L., Söderdahl, G., Potácová, Z., Wersäll, P., Ericzon, B.G., Mattsson, J., Ringdén, O., Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer. Biol. Blood Marrow Transplant. 22 (2016), 676–681.
85. Pardoll, D.M., Inducing autoimmune disease to treat cancer. Proc. Natl. Acad. Sci. USA 96 (1999), 5340–5342.
86. Parkhurst, M.R., Joo, J., Riley, J.P., Yu, Z., Li, Y., Robbins, P.F., Rosenberg, S.A., Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Clin. Cancer Res. 15 (2009), 169–180.
87. Parkhurst, M.R., Yang, J.C., Langan, R.C., Dudley, M.E., Nathan, D.A., Feldman, S.A., Davis, J.L., Morgan, R.A., Merino, M.J., Sherry, R.M., et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19 (2011), 620–626.
88. Pauken, K.E., Sammons, M.A., Odorizzi, P.M., Manne, S., Godec, J., Khan, O., Drake, A.M., Chen, Z., Sen, D.R., Kurachi, M., et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354 (2016), 1160–1165.
89. Paulos, C.M., Carpenito, C., Plesa, G., Suhoski, M.M., Varela-Rohena, A., Golovina, T.N., Carroll, R.G., Riley, J.L., June, C.H., The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci. Transl. Med., 2, 2010, 55ra78.
90. Pegram, H.J., Lee, J.C., Hayman, E.G., Imperato, G.H., Tedder, T.F., Sadelain, M., Brentjens, R.J., Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119 (2012), 4133–4141.
91. Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527 (2015), 249–253.
92. Porter, D.L., Levine, B.L., Kalos, M., Bagg, A., June, C.H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365 (2011), 725–733.
93. Porter, D.L., Hwang, W.T., Frey, N.V., Lacey, S.F., Shaw, P.A., Loren, A.W., Bagg, A., Marcucci, K.T., Shen, A., Gonzalez, V., et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med., 7, 2015, 303ra139.
94. Prosser, M.E., Brown, C.E., Shami, A.F., Forman, S.J., Jensen, M.C., Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Mol. Immunol. 51 (2012), 263–272.
95. Provasi, E., Genovese, P., Lombardo, A., Magnani, Z., Liu, P.-Q., Reik, A., Chu, V., Paschon, D.E., Zhang, L., Kuball, J., et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18 (2012), 807–815.
96. Pulko, V., Davies, J.S., Martinez, C., Lanteri, M.C., Busch, M.P., Diamond, M.S., Knox, K., Bush, E.C., Sims, P.A., Sinari, S., et al. Human memory T cells with a naive phenotype accumulate with aging and respond to persistent viruses. Nat. Immunol. 17 (2016), 966–975.
97. Raman, M.C., Rizkallah, P.J., Simmons, R., Donnellan, Z., Dukes, J., Bossi, G., Le Provost, G.S., Todorov, P., Baston, E., Hickman, E., et al. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy. Sci. Rep., 6, 2016, 18851.
98. Rapoport, A.P., Stadtmauer, E.A., Binder-Scholl, G.K., Goloubeva, O., Vogl, D.T., Lacey, S.F., Badros, A.Z., Garfall, A., Weiss, B., Finklestein, J., et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat. Med. 21 (2015), 914–921.
99. Ren, J., Liu, X., Fang, C., Jiang, S., June, C.H., Zhao, Y., Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res., 2016, 10.1158/1078-0432.ccr-16-1300 Published online November 4, 2016.
100. Ribas, A., Hodi, F.S., Callahan, M., Konto, C., Wolchok, J., Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368 (2013), 1365–1366.
101. Richer, M.J., Lang, M.L., Butler, N.S., T Cell Fates Zipped Up: How the Bach2 Basic Leucine Zipper Transcriptional Repressor Directs T Cell Differentiation and Function. J. Immunol. 197 (2016), 1009–1015.
102. Riches, J.C., Davies, J.K., McClanahan, F., Fatah, R., Iqbal, S., Agrawal, S., Ramsay, A.G., Gribben, J.G., T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 121 (2013), 1612–1621.
103. Riddell, S.R., Watanabe, K.S., Goodrich, J.M., Li, C.R., Agha, M.E., Greenberg, P.D., Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257 (1992), 238–241.
104. Robbins, P.F., Morgan, R.A., Feldman, S.A., Yang, J.C., Sherry, R.M., Dudley, M.E., Wunderlich, J.R., Nahvi, A.V., Helman, L.J., Mackall, C.L., et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29 (2011), 917–924.
105. Robbins, P.F., Lu, Y.C., El-Gamil, M., Li, Y.F., Gross, C., Gartner, J., Lin, J.C., Teer, J.K., Cliften, P., Tycksen, E., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19 (2013), 747–752.
106. Rodgers, D.T., Mazagova, M., Hampton, E.N., Cao, Y., Ramadoss, N.S., Hardy, I.R., Schulman, A., Du, J., Wang, F., Singer, O., et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc. Natl. Acad. Sci. USA 113 (2016), E459–E468.
107. Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., Hacohen, N., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
108. Rosenberg, S.A., Packard, B.S., Aebersold, P.M., Solomon, D., Topalian, S.L., Toy, S.T., Simon, P., Lotze, M.T., Yang, J.C., Seipp, C.A., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319 (1988), 1676–1680.
109. Roybal, K.T., Rupp, L.J., Morsut, L., Walker, W.J., McNally, K.A., Park, J.S., Lim, W.A., Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. Cell 164 (2016), 770–779.
110. Roybal, K.T., Williams, J.Z., Morsut, L., Rupp, L.J., Kolinko, I., Choe, J.H., Walker, W.J., McNally, K.A., Lim, W.A., Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell 167 (2016), 419–432.e16.
111. Roychoudhuri, R., Hirahara, K., Mousavi, K., Clever, D., Klebanoff, C.A., Bonelli, M., Sciumè, G., Zare, H., Vahedi, G., Dema, B., et al. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature 498 (2013), 506–510.
112. Roychoudhuri, R., Clever, D., Li, P., Wakabayashi, Y., Quinn, K.M., Klebanoff, C.A., Ji, Y., Sukumar, M., Eil, R.L., Yu, Z., et al. BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers. Nat. Immunol. 17 (2016), 851–860.
113. Rufer, N., Migliaccio, M., Antonchuk, J., Humphries, R.K., Roosnek, E., Lansdorp, P.M., Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. Blood 98 (2001), 597–603.
114. Schietinger, A., Greenberg, P.D., Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 35 (2014), 51–60.
115. Schietinger, A., Delrow, J.J., Basom, R.S., Blattman, J.N., Greenberg, P.D., Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 335 (2012), 723–727.
116. Schietinger, A., Philip, M., Krisnawan, V.E., Chiu, E.Y., Delrow, J.J., Basom, R.S., Lauer, P., Brockstedt, D.G., Knoblaugh, S.E., Hämmerling, G.J., et al. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Immunity 45 (2016), 389–401.
117. Scholler, J., Brady, T., Binder-Scholl, G., Hwang, W.-T., Plesa, G., Hege, K., Vogel, A., Kalos, M., Riley, J., Deeks, S., et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Science Translational Medicine, 4, 2012, 132Ra153.
118. Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
119. Schumann, K., Lin, S., Boyer, E., Simeonov, D.R., Subramaniam, M., Gate, R.E., Haliburton, G.E., Ye, C.J., Bluestone, J.A., Doudna, J.A., Marson, A., Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc. Natl. Acad. Sci. USA 112 (2015), 10437–10442.
120. Sen, D.R., Kaminski, J., Barnitz, R.A., Kurachi, M., Gerdemann, U., Yates, K.B., Tsao, H.W., Godec, J., LaFleur, M.W., Brown, F.D., et al. The epigenetic landscape of T cell exhaustion. Science 354 (2016), 1165–1169.
121. Singer, M., Wang, C., Cong, L., Marjanovic, N.D., Kowalczyk, M.S., Zhang, H., Nyman, J., Sakuishi, K., Kurtulus, S., Gennert, D., et al. A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells. Cell 166 (2016), 1500–1511.
122. Song, D.-G., Ye, Q., Poussin, M., Harms, G.M., Figini, M., Powell, D.J. Jr., CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 119 (2012), 696–706.
123. Spencer, D., Foster, A.E., and Slawin, K. (2016). Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptides. US Patent 20,160,058,857, filed September 1, 2015, and published March 10, 2016.
124. Stone, J.D., Harris, D.T., Kranz, D.M., TCR affinity for p/MHC formed by tumor antigens that are self-proteins: impact on efficacy and toxicity. Curr. Opin. Immunol. 33 (2015), 16–22.
125. Sukumar, M., Liu, J., Mehta, G.U., Patel, S.J., Roychoudhuri, R., Crompton, J.G., Klebanoff, C.A., Ji, Y., Li, P., Yu, Z., et al. Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. Cell Metab. 23 (2016), 63–76.
126. Symons, H.J., Levy, M.Y., Wang, J., Zhou, X., Zhou, G., Cohen, S.E., Luznik, L., Levitsky, H.I., Fuchs, E.J., The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol. Blood Marrow Transplant. 14 (2008), 499–509.
127. Teachey, D.T., Lacey, S.F., Shaw, P.A., Melenhorst, J.J., Maude, S.L., Frey, N., Pequignot, E., Gonzalez, V.E., Chen, F., Finklestein, J., et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 6 (2016), 664–679.
128. Teng, M.W., Ngiow, S.F., Ribas, A., Smyth, M.J., Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 75 (2015), 2139–2145.
129. Tirosh, I., Izar, B., Prakadan, S.M., Wadsworth, M.H. 2nd, Treacy, D., Trombetta, J.J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352 (2016), 189–196.
130. Topp, M.S., Riddell, S.R., Akatsuka, Y., Jensen, M.C., Blattman, J.N., Greenberg, P.D., Restoration of CD28 expression in CD28- CD8+ memory effector T cells reconstitutes antigen-induced IL-2 production. J. Exp. Med. 198 (2003), 947–955.
131. Turtle, C.J., Hanafi, L.-A., Berger, C., Gooley, T.A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T.M., et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126 (2016), 2123–2138.
132. Tyrakis, P.A., Palazon, A., Macias, D., Lee, K.L., Phan, A.T., Veliça, P., You, J., Chia, G.S., Sim, J., Doedens, A., et al. S-2-hydroxyglutarate regulates CD8(+) T-lymphocyte fate. Nature 540 (2016), 236–241.
133. van den Berg, J.H., Gomez-Eerland, R., van de Wiel, B., Hulshoff, L., van den Broek, D., Bins, A., Tan, H.L., Harper, J.V., Hassan, N.J., Jakobsen, B.K., et al. Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. Mol. Ther. 23 (2015), 1541–1550.
134. van der Windt, G.J., Everts, B., Chang, C.H., Curtis, J.D., Freitas, T.C., Amiel, E., Pearce, E.J., Pearce, E.L., Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36 (2012), 68–78.
135. van Zelm, M.C., Reisli, I., van der Burg, M., Castaño, D., van Noesel, C.J., van Tol, M.J., Woellner, C., Grimbacher, B., Patiño, P.J., van Dongen, J.J., Franco, J.L., An antibody-deficiency syndrome due to mutations in the CD19 gene. N. Engl. J. Med. 354 (2006), 1901–1912.
136. Wang, X., Chang, W.C., Wong, C.W., Colcher, D., Sherman, M., Ostberg, J.R., Forman, S.J., Riddell, S.R., Jensen, M.C., A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118 (2011), 1255–1263.
137. Weiden, P.L., Flournoy, N., Thomas, E.D., Prentice, R., Fefer, A., Buckner, C.D., Storb, R., Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300 (1979), 1068–1073.
138. Weng, N.P., Levine, B.L., June, C.H., Hodes, R.J., Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc. Natl. Acad. Sci. USA 92 (1995), 11091–11094.
139. Wherry, E.J., T cell exhaustion. Nat. Immunol. 12 (2011), 492–499.
140. Wilkie, S., van Schalkwyk, M.C., Hobbs, S., Davies, D.M., van der Stegen, S.J., Pereira, A.C., Burbridge, S.E., Box, C., Eccles, S.A., Maher, J., Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 32 (2012), 1059–1070.
141. Winkelstein, J.A., Marino, M.C., Lederman, H.M., Jones, S.M., Sullivan, K., Burks, A.W., Conley, M.E., Cunningham-Rundles, C., Ochs, H.D., X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine (Baltimore) 85 (2006), 193–202.
142. Wu, C.Y., Roybal, K.T., Puchner, E.M., Onuffer, J., Lim, W.A., Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science, 350, 2015, aab4077.
143. Yu, H., Sotillo, E., Harrington, C., Wertheim, G., Paessler, M., Maude, S.L., Rheingold, S.R., Grupp, S.A., Thomas-Tikhonenko, A., Pillai, V., Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. Am. J. Hematol. 92 (2017), E11–E13.
144. Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M.C., Chen, Y.Y., T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells. Cancer Immunol. Res. 4 (2016), 498–508.
145. Zhang, L., Morgan, R.A., Beane, J.D., Zheng, Z., Dudley, M.E., Kassim, S.H., Nahvi, A.V., Ngo, L.T., Sherry, R.M., Phan, G.Q., et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21 (2015), 2278–2288.
146. Zhang, S.-Q., Parker, P., Ma, K.-Y., He, C., Shi, Q., Cui, Z., Williams, C.M., Wendel, B.S., Meriwether, A.I., Salazar, M.A., Direct measurement of T cell receptor affinity and sequence from naïve antiviral T cells. Sci. Trans. Med., 8, 2016, 341ra77.
147. Zhao, Y., Bennett, A.D., Zheng, Z., Wang, Q.J., Robbins, P.F., Yu, L.Y., Li, Y., Molloy, P.E., Dunn, S.M., Jakobsen, B.K., et al. High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J. Immunol. 179 (2007), 5845–5854.
148. Zhong, S., Malecek, K., Johnson, L.A., Yu, Z., Vega-Saenz de Miera, E., Darvishian, F., McGary, K., Huang, K., Boyer, J., Corse, E., et al. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc. Natl. Acad. Sci. USA 110 (2013), 6973–6978.
149. Zhou, J., Shen, X., Huang, J., Hodes, R.J., Rosenberg, S.A., Robbins, P.F., Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175 (2005), 7046–7052.